Integrated micro-fluidic chip system and method for mass production and enrichment of engineered extracellular vesicles
Through the integration of microfluidic chip system and nano electroporation technology, the yield and quality of engineered extracellular vesicles are improved, the problems of insufficient EVs preparation efficiency and quality in the existing technology are solved, and efficient and convenient EVs enrichment is achieved. and application.
Patent Information
- Application Number
- CN202411170731.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The prior art is difficult to achieve high yield and high quality engineering extracellular vesicles (EVs) preparation in the same system at the same time, and the collection steps of engineered EVs in the prior art are cumbersome and cannot meet the clinical demand for therapeutic EVs. .
An integrated microfluidic chip system is designed, including production areas, capture areas and ammonium ion removal areas, to improve the yield and quality of EVs through nanoelectroporation and electrical stimulation techniques, and to utilize positively charged hydrogel composites Enrichment and application of EVs.
It has achieved a 12-fold increase in the secretion of single-cell EVs and a 30-fold increase in the target nucleic acid content. It can obtain high-quality engineered EVs without centrifugation or purification steps. It is convenient to operate and the product has biosafety and sustained release effects.
Smart Images

Figure CN118988431A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of medical engineering micro-nano equipment, and specifically relates to an integrated microfluidic chip system and method for mass production and enrichment of engineered extracellular vesicles. Background Art
[0002] Cell therapy is increasingly being studied as a new treatment for disease models and patients, and recent studies have shown that the therapeutic benefits of many diseases are driven by extracellular vesicles (EVs) secreted by transplanted cells. EVs have been recognized as important mediators that carry a wealth of molecular information such as DNA, RNA, and proteins, and can serve as communication carriers between cells. Engineered EVs refer to the use of engineering technology to modify the contents of EVs or EV membrane proteins, etc., so that EVs have specific functions and targeting characteristics. Engineered EVs have shown more obvious advantages in disease treatment because their contents can be customized according to disease needs, such as being designed to encapsulate specific gene drugs, small molecule compounds, etc. At present, the most common method for producing engineered EVs is to deliver the required payload to donor cells so that more target payloads are encapsulated in the EVs secreted by donor cells. This approach can produce EVs with higher integrity, but because the biosynthesis and secretion of EVs are regulated by cellular mechanisms, existing technologies have limited improvements in the yield and payload efficiency of EVs secreted by single cells. In response to this, some studies have proposed that additional stimulation of donor cells that produce EVs (such as electrical stimulation, ultrasound, hypoxia, and pH change regulation) can activate the biosynthesis of EVs and accelerate the secretion process to a certain extent. However, there are still many challenges in clinical application: (1) The low amount of EVs secreted by a single cell seriously limits the efficiency of engineering production. Generally, the EV secretion of a single cell is less than 10 3 Particles / cell, and the therapeutic dose of EV required for an adult in clinical practice is generally 0.5-1.4×10 11 (1) The production of particles / cells is seriously insufficient. In order to obtain therapeutic doses of EVs, a large number of donor cells need to be cultured. (2) Clinical applications place high demands on the quality of EVs, such as EV integrity, effectiveness of encapsulating target payloads, and batch consistency. (3) The control of the donor cell culture microenvironment during the production of EVs is limited. For example, it is impossible to remove metabolic waste in the culture environment in real time, which leads to decreased cell activity, changes in EV production and EV content. In summary, the current engineered EVs production strategy is still difficult to meet the clinical demand for therapeutic EVs in terms of production efficiency (e.g., EV yield of a single donor cell) and quality (e.g., EV integrity, drug loading capacity, and consistency between different batches). Therefore, advanced systems for efficient and high-quality engineered EVs have always been widely anticipated, but there are still technical difficulties to achieve them.
[0003] The development of microfluidic technology has provided new ideas for the engineering transformation of EVs. For example, the patent with publication number CN117987467A (20240507) and invention name "A method for preparing therapeutic exosomes using nano-electroporation and other non-endocytic cell transfection" discloses a method of placing donor cells on the surface of a chip, adding various plasmids, other transfection vectors and their combinations to the buffer of the chip, and electroporating the cells placed on the top of the chip surface, so that the cells secrete multiple EVs. This patent solves the problem of mass production of EVs from donor cells to a certain extent. For example, the patent with publication number CN115228521A (20221025) and invention name "Bioparticle separation device and microfluidic chip" discloses a microfluidic chip device that can be used for the separation of extracellular membrane vesicles of large-volume samples. This patent combines microfluidic technology with membrane filtration methods, and solves the problem of improving the separation efficiency and flux of extracellular membrane vesicles to a certain extent.
[0004] However, it is still difficult for existing technologies to achieve both high-yield and high-quality EVs preparation in the same system. At the same time, the existing technologies also have the problem of cumbersome collection steps for engineered EVs. Therefore, it is necessary to propose new methods and strategies. Summary of the invention
[0005] In view of this, the purpose of the present invention is to provide an integrated microfluidic chip system for mass production and enrichment of engineered extracellular vesicles, and a method for producing extracellular vesicles that meet the needs of clinical applications based on this integrated microfluidic chip system, so as to alleviate or partially alleviate the shortcomings of the prior art. The specific technical scheme is as follows.
[0006] An integrated microfluidic chip system for mass production and enrichment of engineered extracellular vesicles, characterized in that the integrated microfluidic chip system comprises a microfluidic chip body and a preset; the microfluidic chip body comprises a cover layer 100, a flow channel layer 200, a liquid reservoir layer 300 and a conductive glass layer 400; the flow channel layer 200, the liquid reservoir layer 300 and the conductive glass layer 400 are integrated together by irreversible bonding, and the cover layer 100 is detachably combined with the flow channel layer 200; the flow channel layer 200 is detachably combined with the liquid reservoir layer 300; the liquid reservoir layer 300 and the conductive glass layer 400 are ... The channel layer is provided with a plurality of reaction zones, micropores and microchannels, including a production zone 201, a capture zone 202 and an ammonium ion removal zone 203, and each reaction zone is separately provided and not connected; the cover layer 100 is provided with a plurality of micropores and microchannels, including an inlet micropore 101 and an outlet micropore 109, which, when combined with the channel layer 200, enable each reaction zone provided on the channel layer 200 to be connected; the first micropore 102 and the second micropore 103 provided on the cover layer 100 are respectively connected to the production zone 201 and the capture zone 202 and the ammonium ion removal zone 203; The fifth micropore 204 and the sixth micropore 205 provided on the cover layer 100 are connected, the first flow channel 106 provided on the cover layer 100 is connected with the eighth micropore 207 provided on the production area 201 and the fourth flow channel 208 provided on the capture area 202, the second flow channel 107 and the third flow channel 108 provided on the cover layer 100 respectively connect the capture area 202 with the ammonium ion removal area 203; the ammonium ion removal area 203 is configured to include a plurality of Tesla flow channels, the Tesla flow channels The SiLa flow channel converges at the bottom and sets a ninth micropore 209 to communicate with the outlet micropore 109; the preset includes one or more of donor cells, working cells, extracellular vesicle adsorption reagents or reagents for nano-electroporation; the donor cells are arranged in the production area 201; the extracellular vesicle adsorption reagents are arranged in the capture area 202; the working cells are arranged in the ammonium ion removal area 203; the reagents for nano-electroporation are arranged in the liquid storage layer 300.
[0007] Furthermore, the production area 201 is configured to have a nanoporous membrane placed inside, and the nanoporous membrane is used to plant the donor cells, and the donor cells are cells that produce engineered extracellular vesicles; the production area 201 is also provided with a seventh micropore 206 connected to the inlet micropore 101.
[0008] Furthermore, a liquid storage area 301 is provided inside the liquid storage layer 300 for placing the reagent for nano-electroporation; the liquid storage area 301 is provided below and connected to the production area 201; the 10th micropore 302 and the 11th micropore 303 are provided on the liquid storage area 301 and are connected to the cover layer 100 and the flow channel layer 200 respectively.
[0009] Furthermore, the extracellular vesicle adsorption reagent is a positively charged hydrogel complex; receptor cells or receptor tissues may also be placed in the extracellular vesicle adsorption reagent; the receptor cells or receptor tissues are cells or tissues that receive engineered extracellular vesicles.
[0010] Preferably, the hydrogel composite comprises 1% chitosan solution, 10% GelMA solution and 2.5% LAP solution, and the volume ratio thereof is 10:10:4.
[0011] The hydrogel complex exhibits strong positive charge in the culture solution and can adsorb negatively charged EVs in the liquid flowing out of the P zone. EVs are rapidly enriched in this area. At the same time, the hydrogel in this area can also be used as a skeleton for receptor cell culture and tissue culture in vitro. These receptor cells or tissues can directly take up EVs in this area to conduct corresponding functional studies. In addition, the EV-rich hydrogel complex material has good biosafety and degradability, can be implanted in the body, and used as a carrier for sustained release of EVs in vivo.
[0012] Furthermore, the working cells are cells capable of adsorbing ammonium ions.
[0013] Furthermore, filter membranes are provided in the microchannels of the cover sheet layer 100 and the channel layer 200 .
[0014] In some embodiments, the working cells are hepatocytes, which have the function of adsorbing or absorbing ammonium ions, a metabolic waste product in the culture medium, and converting them into glutamine, which is beneficial to the cells. The ammonium ion removal zone 203 is designed to include multiple groups of Tesla flow channel structures, which can reduce the liquid flow rate, reduce the shear force and pressure of the fluid on the cells, and fully ensure the removal effect of ammonium ions and the integrity of the cells.
[0015] On the other hand, the present invention also provides a method for preparing and enriching engineered extracellular vesicles, wherein the preparation method is implemented by the above-mentioned integrated microfluidic chip system, comprising the following steps:
[0016] S01: Inject the donor cell suspension into the production area of the flow channel layer of the microfluidic chip, inject the working cell suspension into the Tesla flow channel of the flow channel layer, and culture the cells;
[0017] S02: After the donor cells and the working cells are attached to the wall, a nano-electroporation reagent containing a target gene for follicle activation is injected into the liquid storage area of the liquid storage layer of the microfluidic chip, and the microfluidic chip is connected to an electroporator, with the negative electrode being a conductive glass layer and the positive electrode being a nano-silver electrode, and an electroporation operation is performed to obtain engineered extracellular vesicles in the production area of the flow channel layer. After the first electroporation operation is completed, the nano-electroporation reagent in the liquid storage area is removed;
[0018] S03: placing the positively charged hydrogel complex into the capture area of the flow channel layer, and injecting receptor cells or receptor tissues therein, then combining and fixing the cover sheet layer with the flow channel layer, and connecting the peristaltic pumps through the inlet micropores and outlet micropores of the cover sheet layer;
[0019] S04: running the peristaltic pump and setting the power parameter to 5-10 μL / min, so that the engineered cell extracellular membrane vesicles prepared in the production area enter the capture area and are adsorbed by the positively charged hydrogel complex;
[0020] S05: The peristaltic pump continues to run, so that the cell culture medium in the production area circulates in the entire chip. When the cell culture fluid enters the Tesla flow channel and reacts with the working cells to remove ammonium ions, it continues to circulate back to the production area through the peristaltic pump;
[0021] S06: After the first electroporation operation is completed for 8 hours, multiple non-load electrical stimulations are continued, wherein the reagent used in the non-load electrical stimulation operation is PBS.
[0022] The cell culture fluid purified by the ammonium ion removal zone 203 can flow back to the production zone 201, thereby ensuring a healthy culture environment for the donor cells in the production zone 201, and further providing a circulating production system adapted to the yield and quality of EVs.
[0023] Furthermore, the donor cells are ovarian granulosa cells; the working cells are liver cells; and the target gene with follicle activation effect is miR-130a.
[0024] In some embodiments, the recipient cell is an ovarian granulosa cell; and the recipient tissue is a mouse ovarian tissue.
[0025] Furthermore, the electroporation operation is performed with a voltage of 30 V, a pulse width of 5 ms, a pulse interval of 0.1 s, and a total of 100 pulse cycles.
[0026] The non-load electrical stimulation operation can further stimulate the EV secretion of the donor cells. As a preferred embodiment, the number of non-load electrical stimulation is 1 time.
[0027] Furthermore, the hydrogel composite includes 1% chitosan solution, 10% GelMA solution and 2.5% LAP solution.
[0028] The hydrogel complex of engineered extracellular vesicles containing miR-130a obtained by the above method.
[0029] Beneficial technical effects:
[0030] The present invention first proposes an integrated microfluidic chip system for mass production and enrichment of engineered extracellular vesicles. Three main functional areas are set in the chip system: production area (P area), capture area (U area) and ammonium ion removal area (RE). The three functional areas are independently set without interfering with each other and can independently perform specific functions, such as engineered EVs production and preparation, engineered EVs capture, cell culture fluid purification, etc. After the cover sheet of the integrated microfluidic chip is combined, the microporous flow channels and external pumps set on the cover sheet can connect and connect the functional areas on the microfluidic chip to form a semi-automated circulation system. The semi-automation means that the system does not need to add additional culture medium and nutrients in the process of producing EVs, but only needs to be electrotransformed or electrostimulated by an external power supply, and the entire culture system relies on the self-production and purification of cells in the circulation system to perform its functions.
[0031] Furthermore, the present invention also provides a method for preparing and enriching engineered extracellular vesicles, which relies on the cooperation of three functional areas of the chip system, increases the EV secretion of single cells (12 times higher than that of normal cells), and increases the content of target nucleic acids in EVs by about 30 times. Under the premise of not introducing any chemical substances that are potentially toxic to cells throughout the process, the controllability of the cell culture microenvironment is guaranteed, and the quality of engineered EVs is guaranteed. In addition, the engineered EVs obtained by the method of the present invention do not need to be enriched through centrifugation, purification and other steps. The engineered EVs obtained by adsorption and enrichment in the hydrogel complex through charge action can be directly used, that is, the final product of the present invention does not deviate from the system for producing the product, and the operation is more convenient.
[0032] In particular, the present invention proposes an operation mode of loaded electrotransfer combined with unloaded electrical stimulation, which not only realizes the customized preparation of EVs contents, but also significantly increases the yield of EVs. In addition, the method of the present invention finally prepares a hydrogel complex containing engineered EVs, which can be implanted in the body, has high safety, and has the effect of sustained release of EVs, and has a good prospect for medical application. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, each element or part is not necessarily drawn according to the actual scale. Obviously, the drawings described below are some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained based on these drawings without paying creative labor.
[0034] Summary of reference numerals:
[0035] Cover layer 100, inlet micropore 101, first micropore 102, second micropore 103, third micropore 104, fourth micropore 105, first flow channel 106, second flow channel 107, third flow channel 108, outlet micropore 109; flow channel layer 200, production area 201, capture area 202, ammonium ion removal area 203, fifth micropore 204, sixth micropore 205, seventh micropore 206, eighth micropore 207, fourth flow channel 208, ninth micropore 209, twelfth micropore 210, thirteenth micropore 211; liquid storage layer 300, liquid storage area 301, tenth micropore 302, eleventh micropore 303; conductive glass layer 400.
[0036] Figure 1 An exploded view of an integrated microfluidic chip body in one embodiment of the present invention;
[0037] Figure 2 A schematic diagram of an integrated microfluidic chip cover layer, a flow channel layer and a liquid storage layer in one embodiment of the present invention;
[0038] Figure 3 A schematic diagram of the preparation of an integrated microfluidic chip in one embodiment of the present invention;
[0039] Figure 4 A schematic diagram of the design principle and working process of an integrated microfluidic chip in one embodiment of the present invention;
[0040] Figure 5 The numerical simulation results of mechanical stress in the ammonium ion removal area of different flow channel layers in one embodiment of the present invention;
[0041] Figure 6 This is the result verification of producing engineered EVs by electro-conversion and electro-stimulation in the flow channel layer production area in one of the embodiments of the present invention;
[0042] Figure 7 The effect of the hydrogel complex of the flow channel layer capture zone on the uptake of engineered EVs by receptor cells in one of the embodiments of the present invention;
[0043] Figure 8 This is an experiment in which the PURE chip system promotes granulosa cell proliferation in vitro in one embodiment of the present invention;
[0044] Fig. 9 This is an experiment of activating primordial follicles in in vitro ovarian tissue with a PURE chip in one embodiment of the present invention;
[0045] Fig.10 In one embodiment of the present invention, a process of in situ implantation of a hydrogel complex comprising engineered EVs in a mouse;
[0046] Fig.11This is a verification of the effect of improving ovarian function after in situ implantation of a hydrogel complex containing engineered EVs in mice in one of the embodiments of the present invention. DETAILED DESCRIPTION
[0047] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0048] Herein "and / or" includes any and all combinations of one or more of the associated listed items.
[0049] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.
[0050] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.
[0051] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.
[0052] In this specification, some embodiments may be disclosed in a format of being within a certain range. It should be understood that such description of "being within a certain range" is only for convenience and brevity, and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values within this range. For example, the range The description of should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within this range, for example, 1, 2, 3, 4, 5, and 6. The above rules apply regardless of the breadth of the range.
[0053] Detailed description of some drawings
[0054] Figure 4 :AC are schematic diagrams of the key structures of the EV production area (A), capture area (B) and ammonium ion removal (RE) area (C); D is an overview of the PURE platform; E is the nanopore electroporation of the target nucleic acid drug (miR-130a) into the donor cells in the production area, promoting the release of engineered EVs encapsulated with high-abundance therapeutic miR-130a; F is the porous hydrogel sponge in the capture area that collects engineered EVs based on electrostatic attraction; G is the hepatocytes located in the Tesla flow channel in the ammonium ion removal area that remove ammonium ions from the extracellular environment.
[0055] Figure 5 : A and B are the finite element analysis of fluid shear stress distribution in the PURE chip with Tesla flow channel or S-shaped channel respectively; C is the finite element analysis of compressive stress distribution in the PURE chip with Tesla flow channel or S-shaped channel; D is that the Tesla flow channel has a stronger effect of reducing ammonium ions in the system compared with the S-shaped flow channel.
[0056] Figure 6 : A is the efficiency of electro-delivery of miR-130a in the P zone of the PURE chip system; B is the comparison of the number of EVs secreted by single donor cells in the PURE, Lipo transfection and negative control groups; C is the exploration of the conditions for stimulating EV secretion by electroporation with no load: the horizontal axis is the number of electroporations with no load; D is the comparison of the miR-130 content in the engineered EVs produced by the optimal electric field combination: 1 electro-delivery with load + 1 electro-stimulation without load and the Lipo transfection scheme.
[0057] Figure 7 : A is a laser scanning confocal microscopy (LSCM) fluorescence and bright field images showing engineered EVs captured in the GelMA-chitosan hydrogel in the uptake area, with the red arrow indicating the engineered EV; B is a transmission electron microscopy (TEM) image of the engineered EVs (marked by a red arrow) immobilized by the GelMA-chitosan hydrogel (gray background); C is the efficiency of EV uptake by the GelMA-chitosan hydrogel over time; D is the fluorescence images and quantitative analysis of the fluorescence intensity after PKH67-EV uptake by recipient cells (GCs) at different time schedules in the U zone with or without the hydrogel.
[0058] Figure 8:A is the expression of mTOR signaling pathway-related proteins in recipient cells and donor cells after transfection with miR-130a or NC. B and C are the evaluation of the proliferation capacity of recipient cells after culture on the PURE chip. After the recipient cells were cultured on the corresponding PURE platform for 48 hours, they were taken out for proliferation capacity detection, including counting the proportion of Edu-positive cells after Edu staining (B), and detecting the MTT staining with a microplate reader at different time points after MTT staining (C); D is the comparison of apoptosis rates between recipient cells treated with engineered EV (miR-130a) or control EV (NC); E is the comparison of the proportion of recipient cells and cell cycle stages treated with engineered EV (miR-130a) or control EV (NC).
[0059] Fig. 9 :A is the in vitro activation model of primordial follicles: the ovarian tissue of newborn mice was encapsulated in the hydrogel of the capture area (U area) and stained with HE (HE staining) after 24 hours of culture. P area (-): donor cells were transfected with negative control oligonucleotide; P area (+): donor cells were transfected with miR-130a; RE area (-): lack of hepatocytes in the removal area; RE area (+): presence of hepatocytes in the removal area. Yellow arrows indicate activated follicles, green arrows indicate primordial follicles, and white arrows indicate apoptotic follicles; B and C are the percentages of activated follicles (B) and apoptotic follicles (C) in the primordial follicles of the mouse ovary at the end of 24 hours of tissue culture in the chip uptake area.
[0060] Fig.10 : A shows the surgical process of implanting the EV-rich hydrogel complex produced by the PURE platform into mice; B shows the degradation process of the EV-rich hydrogel complex in vivo.
[0061] Fig.11 :A is HE-stained sections of ovaries treated with hydrogels containing EVs produced under the specified conditions; P area (-): donor cells transfected with negative control oligonucleotides; P area (+): donor cells transfected with miR-130a; RE area (-): absence of hepatocytes in the removal area; RE area (+): presence of hepatocytes in the removal area; B is the percentage of healthy and atretic follicles in the ovaries of each treatment group. Healthy follicles include primary follicles, secondary follicles, and cystic follicles; C is the level of anti-Müller hormone (AMH) in the ovaries of each treatment group. D is the in vitro fertilized eggs obtained from the ovaries of each treatment group, and the situation of in vitro development into blastocysts; E is the probability statistics of in vitro formation of blastocysts in the ovaries of different treatment groups obtained by superovulation.
[0062] Glossary
[0063] The "engineered extracellular vesicles" described in the present invention refer to engineered extracellular vesicles containing target genes obtained by modifying the contents of extracellular vesicles using technical means, and have specific functions.
[0064] Example 1
[0065] This embodiment provides a structural example of an integrated microfluidic chip for mass production and enrichment of engineered extracellular vesicles.
[0066] The integrated microfluidic chip system includes a microfluidic chip body and presets; the microfluidic chip body includes a cover layer 100, a flow channel layer 200, a liquid storage layer 300 and a conductive glass layer 400; the presets include one or more of donor cells, working cells, extracellular vesicle adsorption reagents or reagents for nano-electroporation.
[0067] The flow channel layer 200, the liquid storage layer 300 and the conductive glass layer 400 are integrated together by irreversible bonding; a plurality of reaction zones, micropores and microchannels are arranged on the flow channel layer, including a production zone 201, a capture zone 202 and an ammonium ion removal zone 203, and each reaction zone is arranged separately and not connected; a plurality of micropores and microchannels are arranged on the cover layer 100, including an inlet micropore 101 and an outlet micropore 109, which are connected to each other when reversibly bonded with the flow channel layer 200, including the first micropore 102 and the second micropore 103 arranged on the cover layer 100. The 5th micropore 204 and the 6th micropore 205 are respectively connected with the production area 201, the 1st flow channel 106 arranged on the cover layer 100 is connected with the 8th micropore 207 arranged on the production area 201 and the 4th flow channel 208 arranged on the capture area 202, the 2nd flow channel 107 and the 3rd flow channel 108 arranged on the cover layer 100 respectively connect the capture area 202 with the ammonium ion removal area 203; the ammonium ion removal area 203 is configured to include a plurality of Tesla flow channels, and the Tesla flow channels converge at the bottom and a 9th micropore 209 is arranged to be connected with the outlet micropore 109.
[0068] The donor cells are arranged in the production area 201 ; the extracellular vesicle adsorption reagent is arranged in the capture area 202 ; the working cells are arranged in the ammonium ion removal area 203 ; and the reagent for nano-electroporation is arranged in the liquid storage layer 300 .
[0069] In some embodiments, the plurality of micropores on the cover sheet layer 100 are set to be about 0.8 mm in diameter. The inlet micropore 101 and the outlet micropore 109 are used to connect to the steel needle on the peristaltic pump connecting tube.
[0070] In some embodiments, the production area 201 is configured as a square chamber with a size of 33*33 mm, and a nanoporous membrane is placed inside. The production area 201 is also provided with a seventh micropore 206 communicating with the inlet micropore 101 .
[0071] In some embodiments, the capture chamber 202 is configured as two square chambers with a size of 12.8*12.8, and the cells and the hydrogel complex are placed inside.
[0072] In some embodiments, the ammonium ion removal zone 203 is configured as four groups of Tesla channels with a width of 0.43 mm, and the four groups of Tesla channels are connected and connected at the bottom.
[0073] In some embodiments, the liquid storage layer 300 is provided with a liquid storage area 301, which is arranged below and connected to the production area 201, and is used to place the reagent for nano-electroporation. The liquid storage area 301 is configured as a square chamber with a size of 33*33mm. In addition, the 10th micropore 302 and the 11th micropore 303 are arranged on the liquid storage area 301 and are respectively connected to the 3rd micropore 104 and the 4th micropore 105 arranged on the cover layer 100.
[0074] In some embodiments, filter membranes are disposed in the microchannels of the cover layer 100 and the flow channel layer 200 to filter impurities and cell debris.
[0075] In some embodiments, the conductive glass layer 400 is ITO conductive glass.
[0076] In some embodiments, the flow channel layer 200 may further be provided with a 12th micropore 210 and a 13th micropore 211 , which are connected with the 3rd micropore 104 and the 4th micropore 105 upwards and connected with the 10th micropore 302 and the 11th micropore 303 downwards.
[0077] Example 2
[0078] This embodiment provides an example of a method for preparing the integrated microfluidic chip of Embodiment 1.
[0079] AutoCAD software was used to design the various regions and flow channels of the PURE chip, a polyester photofilm mask was used for photolithography, and the mold was made in a micro-nano clean room. The main process steps are as follows.
[0080] 1. Cleaning silicon wafer
[0081] Select a 4-inch single-polished silicon wafer as the substrate and check with the naked eye for impurities. If there are impurities, wipe the silicon wafer with a dust-free cloth soaked in acetone solution to remove the surface impurities, and then proceed to the next step; if there are no impurities, proceed directly to the next step. Then place the silicon wafer in a glass dish filled with acetone solution (the silicon wafer needs to be submerged in the acetone solution), use maximum power ultrasound to remove residual organic matter on the surface; then use anhydrous ethanol and ultrapure water ultrasonic cleaning in turn. After cleaning, blow dry with a nitrogen gun until there is no obvious water mark on the surface.
[0082] 2. Baking the silicon wafer
[0083] Bake at 150°C for 45 minutes.
[0084] 3. Make the base layer
[0085] Put the baked silicon wafer into the oxygen plasma cleaning machine and clean it with oxygen plasma for 3 minutes. Immediately after the completion, put it in the center of the glue machine and turn on the vacuum pump to fix the silicon wafer. Then draw 2mL of SU8-2010 that has returned to room temperature to the center of the silicon wafer, and then start glueing, and finally get a SU8-2010 base layer with a uniform thickness of 10μm. Bake the silicon wafer containing the SU8-2010 base layer on the heat release table at 95℃ for 3min, then put it on the photolithography machine for exposure and curing, and then place the exposed silicon wafer on the heat release table and bake it at 95℃ for 3min to complete the production of the base layer.
[0086] 4. Make the structural layer
[0087] The silicon wafer with the finished base layer is placed in a coating machine for secondary coating, and the coating method is spin coating. Finally, SU8-2075 with a uniform thickness of 200 μm is obtained.
[0088] After the photoresist is applied, the silicon wafer is left to stand for 5 minutes to reduce the residual prestress in the photoresist. Then the pre-bake is started. The specific parameters of the pre-bake are: first bake at 65℃ for 6 minutes, then bake at 95℃ for 40 minutes. Then the silicon wafer is placed in the photolithography machine for exposure and curing.
[0089] Set the exposure conditions for exposure. Immediately after the exposure, place the silicon wafer on a hot plate for intermediate baking. The specific parameters are: first bake at 65°C for 5 minutes, then bake at 95°C for 14 minutes.
[0090] After post-baking, take out the silicon wafer and cool it to room temperature, then develop it. Put the silicon wafer in a completely clean glass dish, then pour PM-THINNER negative photoresist developer to cover the silicon wafer by about 2mm, and continue shaking until the structural layer is completely revealed. Use silicon wafer tweezers to take out the silicon wafer, rinse it repeatedly with isopropyl alcohol, then rinse it with ultrapure water, and finally blow it dry with nitrogen. Then harden the film, use silicon wafer tweezers to take the silicon wafer to the hot plate, heat it to 150℃ and bake it for 10 minutes.
[0091] 5. Surface modification
[0092] The processed silicon wafer can be used as a master film for subsequent soft lithography chip production. The silicon wafer mold and trichlorosilane are placed in a vacuum dryer, the pressure is set to 100mbar, and the silanization treatment is performed overnight. After the silanization is completed, a silicon wafer mold with surface modification is obtained.
[0093] PURE chip preparation:
[0094] The PURE chip is a multi-layer PDMS device. Each layer is prepared by photolithography, and then batch parts are replicated by soft lithography. Finally, each individual part is obtained by cutting and punching. The main steps of soft lithography are as follows.
[0095] 1. Glue preparation
[0096] The ratio of the basic component to the curing agent is 10:1. The flexibility of the PDMS after molding can be changed by changing the ratio of the basic component to the curing agent according to the experimental requirements. Generally, the larger the ratio, the softer the finished glue.
[0097] 2. Glue
[0098] Use a glass rod to stir the two-component mixture in the plastic cup in a clockwise direction until the mixture produces uniform and dense fine bubbles, then place the plastic cup in a vacuum pump to draw a vacuum until the bubbles are completely removed. It can be stored in a refrigerator at 4°C before use to avoid immediate cross-linking.
[0099] 3. Casting
[0100] Pour the prepared PDMS two-component mixture into the mold, and then put the mold into a vacuum pump to evacuate. After the vacuum is completed, observe with the naked eye whether there are bubbles. If there are no bubbles, the mold can be directly placed in an oven and baked at 70℃ for 120 minutes to ensure that the PDMS is completely cross-linked and formed.
[0101] 4. Draft cutting
[0102] After the PDMS in the mold is completely cross-linked and cooled to room temperature, it is peeled off from the mold and then cut along the pre-marked lines on the PDMS structure.
[0103] 5. Punch
[0104] Use a needle puncher and a customized probe reservoir puncher to punch holes: Use a needle puncher to punch out the sample inlet and outlet ports on each layer. For the sample inlet and outlet ports connected to the chip, the size of the hole should be smaller than the size of the steel needle for connecting the sample inlet and outlet, so that the steel needle can completely fill the sample inlet and outlet ports to avoid leakage. Secondly, use a needle puncher to reserve a position for inserting the top electrode of the nanosilver wire in the cover layer in advance to facilitate subsequent electroporation. Finally, use a customized plasmid reservoir puncher to punch out the storage area in the PDMS reservoir layer.
[0105] 6. Final integration of the chip
[0106] Device integration is achieved through an oxygen plasma activated bonding process.
[0107] (1) Bonding of liquid storage layer and conductive glass layer (ITO glass substrate)
[0108] (2) Bonding of flow channel layer and PC nanoporous membrane
[0109] First, the PDMS was immersed in a 1% volume ratio AEAPS aqueous solution for surface chemical modification for 15 minutes, and then the nanoporous membrane was treated with oxygen plasma (0.75mbr, 18W, 50s). Then, the PDMS chip was taken out, and the surface to be bonded was aligned with the PC nanomembrane. After a light test of bonding, it was placed in an oven (110°C, 60min) to complete the bonding process.
[0110] (3) Bonding of flow channel layer and liquid reservoir layer
[0111] The flow channel layer bonded with the nanoporous membrane is bonded to the liquid storage layer bonded with the ITO glass substrate by oxygen plasma activation, and the specific steps are the same as above.
[0112] (4) The cover layer is fixedly assembled with the integrated chip body
[0113] Align the filter membrane with the inlet / outlet of the U zone and RE zone. The filter membrane is used to filter cell debris and large vesicles and can be replaced at any time. Cover the cover layer on the flow channel layer and align it with each outlet / inlet. In order to build a closed system, the multilayer structure is finally clamped together with uniform stress by a customized polymethyl methacrylate (PMMA) clamp, connected to a sterilized soft catheter and steel needle, and other accessories are assembled at the same time. Finally, the chip is assembled to obtain an integrated PURE chip system. See the schematic diagram Figure 3 .
[0114] Hydrogel preparation process
[0115] 1. Prepare 1% chitosan solution:
[0116] 1g chitosan powder (viscosity: about 100-200mPa·s) was added to 100mL ultrapure water, and then 15ml 1% HCL solution was added. The chitosan was dissolved using a high-speed magnetic stirrer, and after dissolution, the pH value of the chitosan solution was adjusted to about 6 using Na2HPO4 (pH=9). The prepared chitosan solution was placed under strong ultraviolet radiation overnight for sterilization.
[0117] 2. Prepare 10% GelMA solution:
[0118] Dissolve 0.5 g of GelMA solid in 5 mL of ultrapure water and heat the solution in a 60°C water bath for 30 min to ensure that the solid is completely dissolved.
[0119] 3. Preparation of hydrogel complex (GelMA-Chitosan-Hydrogel):
[0120] Mix 2mL of 1% chitosan solution, 2mL of 10% GelMA solution, and 400μL of 2.5% LAP solution in a light-protected environment. Stir the mixture in a 60°C water bath for 10min to ensure thorough and uniform mixing. Pour the GelMA-Chitosan-Hydrogel liquid mixture into the designated mold and expose it to ultraviolet (UV) irradiation for 30s. After the solution solidifies, freeze it at -20°C overnight and then transfer it to a freeze dryer to dry for 2 days. After drying, remove the GelMA-Chitosan-Hydrogel from the mold.
[0121] Example 3
[0122] This embodiment provides an example of a method for engineering EV production, preparation and enrichment based on the integrated microfluidic chip system of Example 1.
[0123] S01: Inject the donor cell suspension (ovarian granulosa cells, including cell culture medium) into the production area of the microfluidic chip flow channel layer, inject the liver cell suspension into the Tesla flow channel of the flow channel layer, and incubate the cells overnight in a cell culture incubator to allow them to adhere to the wall;
[0124] S02: After the donor cells and the working cells are attached to the wall, the nano-electroporation reagent containing miR-130a is injected into the liquid storage area of the liquid storage layer of the microfluidic chip, and the fluidic chip body is connected to the electroporator, the negative electrode is the conductive glass layer, and the positive electrode is the nano-silver electrode, and the electroporation operation is performed. The operation is to set the voltage to 30V, the pulse width to 5ms, the pulse interval to 0.1s, and a total of 100 pulse cycles to obtain engineered extracellular vesicles in the production area of the flow channel layer; after completing the electroporation operation, the nano-electroporation reagent containing miR-130a is removed;
[0125] S03: Place the positively charged hydrogel complex into the capture area of the flow channel layer, and inject receptor cells or receptor tissues into it, then combine the cover layer with the flow channel layer and fix them using a customized clamp, and connect the inlet micropores and outlet micropores of the cover layer to the peristaltic pump steel needles respectively;
[0126] S04: running the peristaltic pump and setting the power parameter to 10 μL / min, so that the engineered cell extracellular membrane vesicles prepared in the production area enter the capture area and are adsorbed by the positively charged hydrogel complex;
[0127] S05: The peristaltic pump continues to run, and the cell culture fluid in the production area enters the Tesla flow channel and reacts with the liver cells (the ammonium ions, a product of cell metabolism, pass through the liver cells in the flow channel layer of the Tesla flow channel, slow down in this area, fully contact with the liver cells, can be absorbed and converted into glutamine that can be used by the cells to provide nutrients that are beneficial to cell growth), and then continues to circulate back to the production area through the peristaltic pump (the purified culture medium and the converted glutamine flow out through the micropores and are transported to the p area through the pipe of the peristaltic pump for recycling. Then the cell culture medium flows from the P area to the U area and then to the RE area);
[0128] S06: After the first electroporation operation is completed for 8 hours, a non-loaded electrical stimulation is continued, and the reagent used for the non-loaded electrical stimulation is PBS.
[0129] The working flow diagram of this embodiment is shown in Figure 4 .
[0130] Example 4
[0131] This example provides performance verification of the method of Example 3.
[0132] The sterilized soft catheter (inner diameter 0.5 mm) and steel needle (outer diameter 0.9 mm) were connected to the inlet micropores of the integrated microfluidic chip (hereinafter referred to as the PURE platform) for cell inoculation. The prepared donor cells (2×10 5 The prepared suspension of ovarian granulosa cells was injected into the nanoporous membrane of the square pool through the corresponding micropores in the P zone; the prepared suspension of hepatocytes was injected into the Tesla flow channel through the corresponding micropores in the RE zone, and the cells were incubated overnight in a cell culture incubator to adhere to the wall.
[0133] 200nM miRNA-130a mimics or corresponding negative control oligonucleotides were suspended in Opti-MEM and injected into the reservoir below the P zone. The positive electrode of the electroporator was clamped on the top silver wire (0.2mm), and the negative electrode was clamped on a custom ITO-coated glass slide. A voltage of 30V (99 pulses, each pulse lasting 5ms, with an interval of 0.1s) was applied between the positive and negative electrodes for delivery. After delivery, the miRNA solution was removed from the storage area and the storage reservoir area was cleaned with 5mg / mL RNase A for 10min to completely remove residual miRNA.
[0134] Effect verification:
[0135] (1) PURE chip removes NH4 + Performance evaluation.
[0136] The ammonium ion removal area 203 provided in the flow channel layer 200 in Example 1 was set as an S-shaped flow channel as a control group. The width of the S-shaped flow channel was 0.43 mm, and the rest of the structure remained the same.
[0137] The results showed that the shear force and pressure of the fluid in the Tesla flow channel were less than those in the S-type flow channel, indicating less interference with the cells. In addition, the liquid flow rate in the Tesla flow channel was significantly reduced, so the output flow rate on the same area was 70% lower than that of the S-type channel. Under the action of the Tesla flow channel structure, the liver cells in the RE area of the PURE platform can effectively convert NH4 + The concentration is reduced from 10mM to 1mM. Therefore, the design of the present invention can achieve the reduction of ammonium ions, reduce its influence on the cell viability of donor cells, and ensure that the cell viability of donor cells is at a high level during the whole culture process. Figure 5 .
[0138] (2) Verification of the PURE chip system’s ability to mass-produce engineered EVs.
[0139] See Figure 6 .like Figure 6 As shown in A, the PURE chip system achieved a transfection efficiency of about 90% for miR-130a-mimics labeled with FAM fluorescent tag in donor GC cells. Compared with natural secretion and liposome transfection (as a benchmark method), Figure 6 As shown in B, the PURE chip system increased the production of EVs by about 4.8 times and about 3.8 times, respectively. The groups were grouped according to the number of non-load electrical stimulation treatments, with the loaded electroporation as the control group 0, and the mass-produced EVs under different non-load electrical stimulations were obtained for nanoparticle size analysis, as shown in Figure 6 As shown in C, one additional non-load electrical stimulation using the PURE chip system resulted in the highest EV yield (up to 1.5 × 10 per cell).5 EVs), which is 10 times higher than the natural secretion level of the cell line. As the number of non-load electrical stimulation treatments increases, the EV production shows a trend of first increasing and then gradually decreasing. Therefore, the mode with the highest production is one load electroporation followed by one non-load electrical stimulation. Finally, according to this optimal mode, Figure 6 The qPCR results in D showed that the levels of the therapeutic component (miR-130a) in the engineered EVs prepared by the PURE chip system were increased by approximately 150-fold and approximately 30-fold compared with the natural secretion and liposome transfection methods, respectively.
[0140] (3) Verification of the ability of the PURE chip to capture EVs in situ.
[0141] After running the PURE chip system for 48 h, the captured EVs were qualitatively and quantitatively analyzed. Figure 7 As shown in A and B, both fluorescence confocal microscopy and transmission electron microscopy (TEM) can observe the presence of a large number of intact EVs trapped in the hydrogel complex. Further quantitative experiments have shown that Figure 7 As shown in C, at around 24 hours, the U region captured approximately 90% of the total EVs generated from the P region.
[0142] To further explore the efficiency of the collected engineered EVs (miR-130a-EVs) taken up by recipient cells, e.g. Figure 7 As shown in D. The donor cells in the P region were stained with PKH67, so the membrane skeleton of the EVs obtained by nano-electroporation was also labeled with green fluorescence. Ovarian granulosa cells (GC) were used as recipient cells and seeded on the hydrogel scaffold in the U region for in situ culture on the chip. Figure 7 The confocal fluorescence image in C shows that when the hydrogel complex is set in the U region, the uptake of EVs in the recipient cells is faster and the uptake amount is higher, indicating that the hydrogel complex set in the U region can not only enrich EVs around the recipient cells, but also promote the uptake of EVs by the recipient cells.
[0143] Example 5
[0144] (1) PURE chip system promotes granulocyte proliferation in vitro:
[0145] Follicles are composed of eggs and granulosa cells. The first step in activating primordial follicles is the proliferation of granulosa cells. Therefore, promoting the proliferation ability of granulosa cells is the first step in improving and activating primordial follicles. Activation of the mTOR signaling pathway is the core step in the proliferation of granulosa cells. Currently, small molecule compounds based on mTOR activation are the mainstream in vitro activation scheme for primordial follicles. However, the efficiency of small molecule compounds entering cells is relatively limited, and there are safety risks, so their clinical application is limited.
[0146] Based on this, the PURE chip system provided by the present invention team can realize the production of extracellular vesicles with specific contents. Specifically, miR-130a with follicle-stimulating effect is delivered into extracellular vesicles through electroporation, and the extracellular vesicles can further efficiently enter the receptor cells, significantly activating the mTOR signaling pathway in the receptor granulosa cells. The self-produced biological components with low immunogenicity and high safety have high application potential in the process of primordial follicle activation.
[0147] This example analyzes the effect of miR-130a-EV on the target protein TSC1 and its downstream key effectors in the mTOR signaling pathway in the recipient cells. Figure 8 As shown in A, Western blot results showed a significant downregulation of TSC1, and upregulation of phosphorylation of mTOR, p70S6K, and 4E-BP1, indicating an increased activation level of the mTOR signaling pathway.
[0148] Subsequently, the recipient cells were subjected to cell proliferation assay using the classic Edu assay ( Figure 8 B) and MTT assay ( Figure 8 C) As shown in the figure, the proliferation rate of recipient GC cells that took up miR-130a-EV produced by PURE was significantly increased.
[0149] The apoptosis level of the recipient cells was detected, such as Figure 8 As shown in D, the flow cytometry results showed that the early and late apoptosis levels of the recipient GCs treated with miR-130a-EVs were significantly downregulated compared with the control group. The cell cycle of the recipient cells was detected. Figure 8 As shown in E, the flow cytometry results showed that miR-130a-EVs caused 65.5% of the recipient cells to enter the S phase and G2 / M phase, i.e., the proliferation phase of the cell cycle, which was an increase of 17.5% compared to the control group, suggesting that it promoted the cell cycle. In general, the in situ cell experiment confirmed that the engineered EVs mass-produced by the PURE chip can efficiently deliver target nucleic acid drugs into target cells. At the same time, this miR-130a-EV can significantly promote the activation of the mTOR signaling pathway in granulosa cells, thereby promoting the proliferation ability of granulosa cells.
[0150] (2) PURE chip activates primordial follicles in ovarian tissue in vitro:
[0151] After verifying the proliferation-promoting effect of recipient cells, the activation effect of miR-130a-EVs on ovarian tissue was verified at the tissue level. The ovaries of newborn mice were placed in the U area of the PURE chip for three-dimensional culture to detect the effect of miR-130a-EV on three-dimensional follicles.
[0152] The results showed that after the activation and proliferation of granulosa cells in the primordial follicles, the enlargement of the oocytes surrounded by granulosa cells indicated the development of primordial follicles. The results of HE staining of ovarian tissue sections showed that Fig. 9 As shown, compared with the control group, the activation rate of primordial follicles by engineered EVs produced by PURE chips was significantly increased by about 30%. At the same time, EVs significantly reduced the apoptosis rate of primordial follicles from 42% (control group) to <5%. In general, the PURE chip system provides a safe and efficient alternative method for the in vitro activation of primordial follicles.
[0153] (3) In situ implantation of hydrogel complexes containing engineered EVs in vivo:
[0154] After capturing mass-produced engineered EVs (miR-130a-EVs), the hydrogels in the U region were implanted in situ into the ovaries of 8-month-old aged mice (implantation process as shown in Fig.10 A).
[0155] The results of surgical implantation of the hydrogel first confirmed the strong bond between the hydrogel and the ovary. Through 21 days of observation, the complete degradation of the hydrogel was verified, and the EVs were continuously released during the degradation process. Fig.10 B).
[0156] (4) Verification of the effect after in situ implantation of hydrogel complexes containing engineered EVs in vivo:
[0157] Ovarian function was systematically measured and evaluated 3 weeks after implantation to determine the recovery of ovarian function, including the proportion of healthy and atrophic follicles, anti-Müllerian hormone (AMH) levels, and oocyte development potential. Fig.11 As shown in AB, the ovaries of the aged mice in the negative control group (P(-)RE(-) group) showed a decrease in healthy follicles at all stages (primordial follicles, primary follicles, secondary follicles and mature follicles), accompanied by signs of aging ovaries such as oocyte degeneration, peripheral granulosa cell apoptosis and follicle atrophy. However, the PURE chip mass-produced engineered EVs (P(+)RE(+) group) significantly improved the quality of follicles in aged ovaries, such as an increase in the proportion of healthy oocytes (an increase of 45.8% compared with the P(-)RE(-) group) and a decrease in the proportion of atrophic follicles (a decrease of 68.4% compared with the P(-)RE(-) group). The level of anti-Müllerian hormone (AMH) in ovarian tissue was tested, and the results showed that the AMH level in the P(+)RE(+) group was 3.4 times higher than that in the P(-)RE(-) group, further confirming that the ovarian function of aged mice was restored after the miR-130a-EV treatment group (as shown in Figure 2). Fig.11 C).
[0158] To further evaluate the quality and developmental potential of oocytes, oocytes from aged mice obtained by superovulation were subjected to in vitro fertilization. The developmental potential of oocytes in the P(-)RE(-) group after fertilization was very low, with only 10% of the zygotes able to develop into blastocysts. However, the blastocyst formation rate in the P(+)RE(+) group was enhanced by more than 4 times, indicating that the treatment of PURE chip-produced engineered EVs significantly improved the quality of oocytes (e.g. Fig.11 DE). In addition, the blastocyst formation rate of the P(+)RE(+) group was significantly higher than that of the P(+)RE(-) group and the P(-)RE(+) group, which further verified the importance of the two functional regions in the efficient production of engineered EVs.
[0159] In summary, the PURE chip system can produce hydrogel complexes containing engineered EVs with in vivo application prospects, which can be implanted in the body and slowly release EVs, and has good medical application prospects.
[0160] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative rather than restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.
Claims
1. An integrated microfluidic chip system for mass production and enrichment of engineered extracellular vesicles, characterized in that: The integrated microfluidic chip system comprises a microfluidic chip body and a preset; the microfluidic chip body comprises a cover layer (100), a flow channel layer (200), a liquid storage layer (300) and a conductive glass layer (400); the flow channel layer (200), the liquid storage layer (300) and the conductive glass layer (400) are integrated together by irreversible bonding, and the cover layer (100) and the flow channel layer (200) are detachably combined; a plurality of reaction areas, micropores and microchannels are arranged on the flow channel layer, including a production area (201) , a capture zone (202) and an ammonium ion removal zone (203), and each reaction zone is separately arranged and not connected; a plurality of micropores and microchannels are arranged on the cover layer (100), including an inlet micropore (101) and an outlet micropore (109), which, when combined with the channel layer (200), enable each reaction zone arranged on the channel layer (200) to be connected; the first micropore (102) and the second micropore (103) arranged on the cover layer (100) are respectively connected to the fifth micropore (204) and the fifth micropore (205) arranged on the production zone (201). The first flow channel (106) provided on the cover sheet layer (100) is connected to the 6th micropore (205) provided on the production zone (201) and the 4th flow channel (208) provided on the capture zone (202); the 2nd flow channel (107) and the 3rd flow channel (108) provided on the cover sheet layer (100) respectively connect the capture zone (202) and the ammonium ion removal zone (203); the ammonium ion removal zone (203) is configured to include a plurality of Tesla flow channels, the Tesla flow channels The SiLa flow channel converges at the bottom and sets a ninth micropore (209) to communicate with the outlet micropore (109); the preset includes one or more of donor cells, working cells, extracellular vesicle adsorption reagents or reagents for nano-electroporation; the donor cells are arranged in the production area (201); the extracellular vesicle adsorption reagents are arranged in the capture area (202); the working cells are arranged in the ammonium ion removal area (203); and the reagents for nano-electroporation are arranged in the liquid storage layer (300).
2. The integrated microfluidic chip system according to claim 1, characterized in that: The production area (201) is configured to have a nanoporous membrane placed inside, and the nanoporous membrane is used to plant the donor cells, and the donor cells are cells that produce engineered extracellular vesicles; the production area (201) is also provided with a seventh micropore (206) connected to the inlet micropore (101).
3. The integrated microfluidic chip system according to claim 1, characterized in that: The liquid storage layer (300) is provided with a liquid storage area (301) for storing the reagent for nano-electroporation; the liquid storage area (301) is arranged below and connected to the production area (201); the liquid storage area (301) is provided with a 10th micropore (302) and an 11th micropore (303) which are respectively connected to the cover layer (100) and the flow channel layer (200).
4. The integrated microfluidic chip system according to claim 1, characterized in that: The extracellular vesicle adsorption reagent is a positively charged hydrogel complex; receptor cells or receptor tissues may also be placed in the extracellular vesicle adsorption reagent; the receptor cells or receptor tissues are cells or tissues that receive engineered extracellular vesicles.
5. The integrated microfluidic chip system according to claim 1, characterized in that: The working cells are cells capable of adsorbing ammonium ions.
6. A method for preparing and enriching engineered extracellular vesicles, characterized in that: The method is implemented based on the integrated microfluidic chip system according to any one of claims 1 to 5, comprising the following steps: S01: Inject the donor cell suspension into the production area of the flow channel layer of the microfluidic chip, inject the working cell suspension into the Tesla flow channel of the flow channel layer, and culture the cells; S02: After the donor cells and the working cells are attached to the wall, a nano-electroporation reagent containing a target gene for follicle activation is injected into the liquid storage area of the liquid storage layer of the microfluidic chip, and the microfluidic chip is connected to an electroporator, with the negative electrode being a conductive glass layer and the positive electrode being a nano-silver electrode, and an electroporation operation is performed to obtain engineered extracellular vesicles in the production area of the flow channel layer. After the first electroporation operation is completed, the nano-electroporation reagent in the liquid storage area is removed; S03: placing the positively charged hydrogel complex into the capture area of the flow channel layer, and injecting receptor cells or receptor tissues therein, then combining and fixing the cover sheet layer with the flow channel layer, and connecting the peristaltic pumps through the inlet micropores and outlet micropores of the cover sheet layer; S04: running the peristaltic pump and setting the power parameter to 5-10 μL / min, so that the engineered cell extracellular membrane vesicles prepared in the production area enter the capture area and are adsorbed by the positively charged hydrogel complex; S05: The peristaltic pump continues to run, so that the cell culture medium in the production area circulates in the entire chip. When the cell culture medium enters the Tesla flow channel and reacts with the working cells, the ammonium ions are removed and then continue to circulate back to the production area through the peristaltic pump. S06: After the first electroporation operation is completed for 8 hours, multiple non-load electrical stimulations are continued, wherein the reagent used for the non-load electrical stimulation is PBS.
7. The method according to claim 6, characterized in that The donor cells are ovarian granulosa cells; the working cells are liver cells; and the target gene with follicle activation effect is miR-130a.
8. The method according to claim 6, characterized in that The electroporation operation was performed with a voltage of 30 V, a pulse width of 5 ms, a pulse interval of 0.1 s, and a total of 100 pulse cycles.
9. The method according to claim 6, characterized in that The hydrogel complex includes 1% chitosan solution, 10% GelMA solution and 2.5% LAP solution.
10. A hydrogel complex of engineered extracellular vesicles containing miR-130a obtained by the method according to any one of claims 6 to 9.
Citation Information
Patent Citations
Microfluidic channel, microfluidic chip and method for preparing vesicles
CN111286456A
Biological particle separation device and micro-fluidic chip
CN115228521A
Separation and identification method of extracellular vesicles
CN116773500A
Method for preparing therapeutic exosome by utilizing nano electroporation and other non-endocytosis cell transfection
CN117987467A
Methods for generating therapeutic delivery platforms
US20210268121A1
Cited By
Carrier synthesis preparation system and carrier synthesis preparation method
CN120460036A
A computer-aided design, function simulation and quality control method and system of engineered exosomes
CN122758639A
